Serum-free Media Market
Number of pages: 100 | Report Format: PDF | Published date: April 28, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 1.5 billion |
|
Revenue Forecast in 2031 |
US$ 3.7 billion |
|
CAGR |
7.5% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Media Type, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global serum-free media market was valued at US$ 1.5 billion in 2022 and is expected to register a revenue CAGR of 7.5% to reach US$ 3.7 billion by 2031.
Serum-free Media Market Fundamentals
Serum-free media is designed to grow certain cell types or perform specific applications without serum. Using serum-free medium (SFM) is an essential technique that permits cell culture to be performed under a predetermined set of circumstances that are as devoid of confounding factors as feasible. Advantages of serum-free media include improved definition, more consistent performance, and easier purification and downstream processing. The serum-free medium contains unspecified animal-derived products such as serum albumin (purified from blood), hormones, growth factors, proteins, etc.
Serum-free is becoming more popular, particularly in the biopharmaceutical business, where serum is viewed as a possible health threat and a source of undesirable contamination. Serum-free media normally do not include an animal or human serum, although they may contain serum elements like albumin, sometimes provided as supplements. In rare situations, albumin has been proven to enhance brain growth by stimulating astrocytes to produce and release oleic acid and glutamate, which causes neuronal differentiation. However, albumin may be added to media for a fraction of the cost of complete animal serum, which contains growth factors, hormones, and physiologically active anti-inflammatory medicines.
Several serum-free media (SFM) are being researched to develop commercial SFM as an alternative to fetal bovine serum (FBS) for growing mesenchymal stromal cells (MSCs) for therapeutic purposes. Safety, effectiveness, consistency, and reproducibility are all reasons for moving to serum-free media. Furthermore, variables including basal media, glucose content in basal media, stable glutamine, Mononuclear cells (MNCs) plating density, MSC expansion seeding density (SD), growth factor supplementation, and cell culture plastic surface quality must be considered.
Various SFMs are commercially available for diverse cell types and test purposes. The use of culture medium is rising exponentially, and novel FBS alternatives for cell-based treatments are continually being developed. To attract more clients, media companies encourage the use of such terms in a variety of publications.
[34]
Serum-free Media Market Dynamics
The market is driven by the rising prevalence of infectious and chronic illnesses, obesity, aging, and early detection and treatment of these disorders. The growing demand for recombinant proteins and medicinal pharmaceuticals and expanding R&D for innovative product launches, partnerships, mergers, and acquisitions by market-leading competitors are driving industry dynamics. PromoCell, for instance, announced a 3rd generation melanocyte culture portfolio for developing human and juvenile melanocytes in March 2021, comprising M3 (Melanocyte Growth Medium), a BPE-free and PMA-free medium. Furthermore, developments in bioprocessing methods and CRO enhancements for improving the drug discovery process boost the global serum-free culture market.
Customized cell culture medium manufacturers are improving their output capacity. Thermo Fisher Scientific, a provider of scientific instruments, reagents and consumables, and software services in the United States, promote their Gibco serum-free medium, promoting enhanced cell growth and viability. Serum-free media manufacturers produce mediums that allow for exact evaluations of cellular function and consistent performance. In a serum-free medium, enhanced detection of cellular mediators and improved control over physiological response are desirable. Because there are no proteins and only tiny quantities of human recombinant insulin, downstream processing, and regulatory compliance are facilitated.
Serum-free Media Market Ecosystem
The global serum-free media market is analyzed from the following perspective by media type, end user, and region.
Serum-free Media Market by Media Type
Based on the media type, the global serum-free media market is segmented into CHO cell media, protein expression media, immunology media, insect cell media, hybridoma media, stem cell media, and chemically defined media.
The CHO cell media segment will likely dominate the market during the forecast period. The benefits of Chinese hamster ovary (CHO) cells in recombinant therapeutic protein (RTP) synthesis, essential components of SFM, are being improved to various degrees and proportions. Because of their ability to create complex proteins identical to those present in humans, CHO cells have emerged as the gold standard in the antibody manufacturing process. Because of their excellent tolerance for variations in cell density, oxygen levels, pH, or temperature, they are perfect for large-scale production. This leads to their excellent stability and flexibility for culture conditions that are protein-free, animal-free, and serum-free. As a result, biopharmaceutical companies are using CHO cell culture medium to produce biomedicines, increasing the global sector share.
For SFM optimization, the Plackett Burman method (PBM) and the response surface approach are commonly employed. They can be supplemented with other statistical methods, such as non-parametric Gaussian kernel regression.
Serum-free Media Market by End User
[67]
Based on end user, the global serum-free media market is segmented into biopharma industry, clinical research organizations, and others.
The biopharmaceutical industry will have a global market share in 2022, owing to improved production capacity, the incidence of infectious and chronic illness, and the desire for innovative therapeutic medications. The revolution in the life science sectors, as well as increased private and public sector investment in research and development for the production of vaccines, monoclonal antibodies, and other therapeutic proteins for the treatment of infectious and chronic diseases such as COVID-19 and cancer, are factors promoting global segment growth.
Serum-free Media Market by Region
Based on region, the global serum-free media market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America is likely to dominate the market during the forecast period. Cell-based assay developments include cellular expression, pluripotent stem cell research, cytotoxicity tests, etc. This is largely owing to multiple biopharmaceutical businesses in the area, research funding for cell and stem cell-based products, many CROS, and a well-established hospital infrastructure. Other reasons contributing to the expansion of the serum-free media sector in the nation include the growing use of serum-free media culture to create vaccines for chronic illnesses and an increase in demand for diverse recombinant proteins.
Europe regions are growing at a significant rate during the forecast period. The primary challenge confronting the worldwide serum-free media market is affordability. This technology is commonly used by researchers and diagnosticians in both developed and developing countries since it provides reliable information and rapid findings. As a result, the cost of serum-free medium technology is greater than that of other cell culture technologies. Serum-free media, a rapidly emerging area of biotechnology and biopharma in Germany with academic institutions, enables researchers to monitor and assess interactions between cells and pathogens such as viruses and bacteria, investigate medication effects, and examine the aging process. Government research institutions make small investments in areas such as gene editing. These features promote Germany's serum-free media business.
In the upcoming years, Asia-Pacific is likely to create significant income prospects. This is due to the region's high potential for producing serum-free medium. Because this technique is expected to be useful in preventing and treating complex diseases such as mental illness, cancer, heart disease, and HIV infection, the Asia-Pacific region is expected to generate lucrative growth opportunities, bolstering the region's serum-free media market.
China held a considerable market share of about of the worldwide market. Despite all measures and personal cleanliness standards, the frequency of infectious and chronic illnesses is increasing in China. The prevalence of infectious disorders has led to advancements in serum-free media research and development, expected to boost the entire serum-free media market. Government support for the production of vaccines based on cell cultures, friendly regulatory requirements, low manufacturing costs, increased research and development capabilities with the assistance of key manufacturers, a greater focus on collaboration with China, and rising stem cell and cell culture therapies will all contribute to market expansion in China.
Serum-free Media Market Competitive Landscape
Some of the prominent market players in the global serum-free media market include,
These companies are involved in developing, producing, and marketing SFM and its accessories to satisfy the needs of diverse sectors.
Serum-free Media Market Strategic Development
Serum-free media are media designed to grow a certain cell type or perform a specific application without serum. Using serum-free medium (SFM) is an essential technique that permits cell culture to be performed under a predetermined set of circumstances that are as devoid of confounding factors as feasible.
North America is the key growth region in the global serum-free media market.
The estimated market size of the serum-free media market in 2031 will be US$ 3.7 billion.
The revenue CAGR of the serum-free media market during the forecast period will be 7.5%.
Some prominent global serum-free media market players include Illumina, Inc., Thermo Fisher Scientific, Inc., and Sigma Aldrich.
*Insights on financial performance are subject to the availability of information in the public domain